{"id":636462,"date":"2023-02-01T20:00:02","date_gmt":"2023-02-01T20:00:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=636462"},"modified":"2023-02-01T20:00:02","modified_gmt":"2023-02-01T20:00:02","slug":"familial-chylomicronemia-syndrome-market-to-observe-impressive-growth-during-the-forecast-period-20192032-evaluates-delveinsight-key-companies-ionis-akcea-arrowhead-pharma-amryt-pharma","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/familial-chylomicronemia-syndrome-market-to-observe-impressive-growth-during-the-forecast-period-20192032-evaluates-delveinsight-key-companies-ionis-akcea-arrowhead-pharma-amryt-pharma_636462.html","title":{"rendered":"Familial Chylomicronemia Syndrome Market to Observe Impressive Growth During the Forecast Period (2019-2032), Evaluates DelveInsight | Key Companies – Ionis, Akcea, Arrowhead Pharma, Amryt Pharma"},"content":{"rendered":"
\n
\"Familial<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
The Familial Chylomicronemia Syndrome market is anticipated to grow in the coming years owing to the improvement in the diagnosis rate, the rise in the number of companies taking an interest in the development of drugs, the ready uptake of premium-price agents like oligonucleotides with better clinical profiles, non-adherence of the patients to the extremely restrictive low-fat diet and patients with significant interference in their daily activities who will seek for medications.<\/div>\n

Some of the leading companies in the Familial Chylomicronemia Syndrome therapeutics market include Arrowhead, Akcea Therapeutics, Ionis Pharmaceuticals, Amryt Pharma, <\/strong>and others.<\/em><\/p>\n

DelveInsight’s “Familial Chylomicronemia Syndrome Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Familial Chylomicronemia Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The Familial Chylomicronemia Syndrome market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Familial<\/p>\n

Familial Chylomicronemia Syndrome: An Overview<\/strong><\/p>\n

FCS is a rare autosomal recessive metabolic disorder caused by a mutation in lipoprotein lipase. Lipoprotein lipase is a digestive enzyme in the blood that helps the body break down chylomicrons. People with FCS are either unable to make lipoprotein lipase or have a broken form. This leads to elevated triglycerides and chylomicrons in the plasma, which causes an array of symptoms, including serious episodes of acute pancreatitis. It correlates with significant morbidity and distress among the patients.<\/p>\n

Familial Chylomicronemia Syndrome Market Key Facts<\/strong><\/p>\n